Expert Opinion on Investigational Drugs

Papers
(The TQCC of Expert Opinion on Investigational Drugs is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond89
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer83
Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases78
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?77
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials74
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects69
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives63
Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential59
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?56
Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors56
The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success56
Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer50
Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies45
Fezolinetant in the treatment of vasomotor symptoms associated with menopause43
The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs42
Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)42
Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–Positive Generalized Myasthenia Gravis41
Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas41
ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease41
CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress39
Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma36
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer34
Lecanemab (BAN2401): an anti–beta-amyloid monoclonal antibody for the treatment of Alzheimer disease33
Monoclonal antibody therapies in the management of SARS-CoV-2 infection32
MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma32
New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine31
Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics30
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers29
Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action29
Therapies in preclinical and clinical development for Angelman syndrome28
Investigational drugs for the treatment of diffuse large B-cell lymphoma27
Immunotherapies in clinical development for biliary tract cancer27
Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy26
Repurposing elesclomol, an investigational drug for the treatment of copper metabolism disorders26
Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA)24
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer23
JAK inhibitors for rheumatoid arthritis22
AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence21
Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment21
Sprifermin: a recombinant human fibroblast growth factor 18 for the treatment of knee osteoarthritis20
Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases20
Translesion synthesis inhibitors as a new class of cancer chemotherapeutics20
The time to offer treatments for COVID-1920
Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?20
New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs19
Anti-diabetic drugs and NASH: from current options to promising perspectives18
What have we learned from past failures of investigational drugs for Alzheimer’s disease?18
Ipilimumab: an investigational immunotherapy for glioblastoma18
Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities17
An update on investigational therapies that target STAT3 for the treatment of cancer17
Investigational drugs in clinical trials for macular degeneration17
Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options17
Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy17
Aromatase inhibitors for the treatment of endometriosis: a systematic review about efficacy, safety and early clinical development17
Asciminib: an investigational agent for the treatment of chronic myeloid leukemia16
Investigational drugs and nutrients for human longevity. Recent clinical trials registered in ClinicalTrials.gov and clinicaltrialsregister.eu16
Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia16
Current emerging and investigational drugs for the treatment of chronic hand eczema16
Immune checkpoint inhibitors for the treatment of sepsis:insights from preclinical and clinical development15
Lorecivivint, an intra-articular potential disease-modifying osteoarthritis drug15
Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes15
Bladder cancer: shedding light on the most promising investigational drugs in clinical trials14
Post-pancreatitis diabetes mellitus: investigational drugs in preclinical and clinical development and therapeutic implications14
Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development14
Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease14
Development of gamma-tocotrienol as a radiation medical countermeasure for the acute radiation syndrome: current status and future perspectives14
Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib14
Telacebec: an investigational antibacterial for the treatment of tuberculosis (TB)14
Emerging agents for the treatment and prevention of stroke: progress in clinical trials14
Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy13
IgA nephropathy: an overview of drug treatments in clinical trials13
Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know13
Targeting Ebola virus replication through pharmaceutical intervention13
Novel systemic treatment approaches for metastatic pancreatic cancer13
Current options and investigational drugs for the treatment of eosinophilic esophagitis13
Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)13
Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond12
An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension12
Emerging treatments for chronic urticaria12
Low-dose aspirin for early COVID-19: does the early bird catch the worm?12
A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson’s disease: translational gaps or a failing industry innovation model?12
Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers12
Selective endothelin A receptor antagonism in patients with proteinuric chronic kidney disease11
Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individuals11
Angiogenesis in biliary tract cancer: targeting and therapeutic potential11
Adrecizumab: an investigational agent for the biomarker-guided treatment of sepsis11
Derazantinib: an investigational drug for the treatment of cholangiocarcinoma11
Camrelizumab: an investigational agent for hepatocellular carcinoma11
Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies11
Investigational neuroprotective compounds in clinical trials for retinal disease11
Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine11
Advances in targeting estrogen synthesis and receptors in patients with endometriosis11
ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer’s disease10
Investigational drugs for the treatment of kidney transplant rejection10
Recent developments for new investigational JAK inhibitors in psoriatic arthritis10
Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects10
Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents10
Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy10
Therapeutic angiogenesis in coronary artery disease: a review of mechanisms and current approaches10
Cystic fibrosis – Ten promising therapeutic approaches in the current era of care10
Circadian rhythms in diabetic retinopathy: an overview of pathogenesis and investigational drugs10
COR388 (atuzaginstat): an investigational gingipain inhibitor for the treatment of Alzheimer disease10
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?10
Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential10
Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata10
Batten disease: an expert update on agents in preclinical and clinical trials9
Still grasping at straws: donanemab in Alzheimer’s disease9
Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclini9
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects9
Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials9
Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development9
Current status and future expectations of nanobodies in oncology trials9
Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs9
Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics9
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials9
Oregovomab: an investigational agent for the treatment of advanced ovarian cancer9
Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development9
Durvalumab: an investigational agent for unresectable hepatocellular carcinoma9
Cardiac fibrosis: emerging agents in preclinical and clinical development9
Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease9
A randomized, double-blind, parallel pharmacokinetic study comparing the trastuzumab biosimilar candidate, AryoTrust®, and reference trastuzumab in healthy subjects9
Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation9
Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development9
0.039786100387573